ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb

ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb
Reuters - 33 minutes ago
PEG-Interferon lambda is a Targeted Type 3 interferon in development for Hepatitis C SEATTLE--(Business Wire)-- ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced the initiation of a Phase 2 ...
ZymoGenetics Commences Phase 2 Clinical Trial Of PEG-Interferon Lambda In Hepatitis C With Bristol-Myers Squibb - Quick Facts - RTT News